Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May;7(5):279-89.
doi: 10.1038/nrendo.2011.12. Epub 2011 Feb 8.

Management of Cushing disease

Affiliations
Review

Management of Cushing disease

Nicholas A Tritos et al. Nat Rev Endocrinol. 2011 May.

Abstract

Cushing disease is caused by a corticotroph tumor of the pituitary gland. Patients with Cushing disease are usually treated with transsphenoidal surgery, as this approach leads to remission in 70-90% of cases and is associated with low morbidity when performed by experienced pituitary gland surgeons. Nonetheless, among patients in postoperative remission, the risk of recurrence of Cushing disease could reach 20-25% at 10 years after surgery. Patients with persistent or recurrent Cushing disease might, therefore, benefit from a second pituitary operation (which leads to remission in 50-70% of cases), radiation therapy to the pituitary gland or bilateral adrenalectomy. Remission after radiation therapy occurs in ∼85% of patients with Cushing disease after a considerable latency period. Interim medical therapy is generally advisable after patients receive radiation therapy because of the long latency period. Bilateral adrenalectomy might be considered in patients who do not improve following transsphenoidal surgery, particularly patients who are very ill and require rapid control of hypercortisolism, or those wishing to avoid the risk of hypopituitarism associated with radiation therapy. Adrenalectomized patients require lifelong adrenal hormone replacement and are at risk of Nelson syndrome. The development of medical therapies with improved efficacy might influence the management of this challenging condition.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Eur J Endocrinol. 2009 Jun;160(6):1003-10 - PubMed
    1. J Neurosurg. 2008 Jan;108(1):9-18 - PubMed
    1. Neurosurg Focus. 2007;23(3):E9 - PubMed
    1. J Clin Endocrinol Metab. 2008 Jul;93(7):2454-62 - PubMed
    1. J Clin Endocrinol Metab. 1987 Nov;65(5):906-13 - PubMed

MeSH terms

LinkOut - more resources